A molecule that kills the malaria parasite and leaves healthy cells intact has been developed by researchers from The University of Queensland and The Australian National University (ANU).
Researchers from UQ’s Institute for Molecular Bioscience (IMB) took a protein, PF4, discovered by ANU researchers and engineered it into a smaller molecule more suitable for drug development.
The joint team then tested the resulting peptide to determine how it destroyed the malaria parasite, Plasmodium, while leaving human cells untouched.
UQ’s Dr Nicole Lawrence said the designer peptide was smaller than the parent protein, allowing better therapeutic targeting without unwanted side effects.
“The most critical feature of the peptide we designed is its big window of safety over healthy cells, because the peptide specifically targets cells that are infected with malaria parasites,” she said.
“The peptide only kills the Plasmodium parasite and doesn’t damage the rest of the infected cell.
“Our next step is to improve the potency of the designer peptide and lessen the chance of future drug resistance through dual targeting of Plasmodium’s internal membranes and key enzymes.”
Malaria infected more than 200 million people, with almost half-a-million people dying, in 2016, according to the World Health Organization, and current treatments are at serious risk of becoming less effective due to emerging drug resistance.
Associate Professor Brendan McMorran from ANU’s John Curtin School of Medical Research said the team was a step closer to developing a new and effective treatment for malaria.
“PF4, which my research group at ANU identified in previous work, is the only human protein known to kill malarial parasites.”
“We have shown that this peptide kills the parasite in a way that is completely different to how current antimalarial drugs work,” Dr McMorran said.
“This is important because finding new ways to kill the parasite will help us overcome the drug-resistance problems.”
The study involved expertise from the peptide researchers at UQ’s Institute for Molecular Bioscience and several disciplines from the John Curtin School of Medical Research, and the ANU Research School of Biology.
It was published in international scientific journal Cell Chemical Biology.
